Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew B Lassman

Showing results (1-10 of 145) with videos related to

Pageof 15
Sort By:
Oncology (Williston Park, N.Y.)|June 21, 2013
Oligodendrogliomas: questions answered, answers questionedAndrew B Lassman
CNS Oncology|November 7, 2015
Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?Andrew B Lassman
Current Neurology and Neuroscience Reports|April 23, 2004
Molecular biology of gliomasAndrew B Lassman
Current Oncology Reports|December 19, 2012
Success at last: a molecular factor that informs treatmentAndrew B Lassman
Targeted Oncology|September 3, 2010
Molecular markers in gliomas: impact for the clinicianSilvia Hofer, Andrew B Lassman
Current Oncology Reports|April 29, 2010
Advances in the treatment of malignant gliomasMustafa Khasraw, Andrew B Lassman
Nature Reviews. Neurology|December 3, 2009
Neuro-oncology: late neurocognitive decline after radiotherapy for low-grade gliomaMustafa Khasraw, Andrew B Lassman
Neuro-Oncology|June 2, 2020
Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?Aya Haggiagi, Andrew B Lassman
Hematology/Oncology Clinics of North America|November 23, 2006
Glioma oncogenesis and animal models of glioma formationYelena Lyustikman, Andrew B Lassman
Nature Reviews. Clinical Oncology|July 30, 2010
Medical oncology: Optimizing chemotherapy and radiotherapy for anaplastic gliomaPatrick G Morris, Andrew B Lassman
Pageof 15

Showing results (1-10 of 145) with videos related to

Sort By:
Pageof 15
Oncology (Williston Park, N.Y.)|June 21, 2013
Oligodendrogliomas: questions answered, answers questionedAndrew B Lassman
CNS Oncology|November 7, 2015
Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?Andrew B Lassman
Current Neurology and Neuroscience Reports|April 23, 2004
Molecular biology of gliomasAndrew B Lassman
Current Oncology Reports|December 19, 2012
Success at last: a molecular factor that informs treatmentAndrew B Lassman
Targeted Oncology|September 3, 2010
Molecular markers in gliomas: impact for the clinicianSilvia Hofer, Andrew B Lassman
Current Oncology Reports|April 29, 2010
Advances in the treatment of malignant gliomasMustafa Khasraw, Andrew B Lassman
Nature Reviews. Neurology|December 3, 2009
Neuro-oncology: late neurocognitive decline after radiotherapy for low-grade gliomaMustafa Khasraw, Andrew B Lassman
Neuro-Oncology|June 2, 2020
Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?Aya Haggiagi, Andrew B Lassman
Hematology/Oncology Clinics of North America|November 23, 2006
Glioma oncogenesis and animal models of glioma formationYelena Lyustikman, Andrew B Lassman
Nature Reviews. Clinical Oncology|July 30, 2010
Medical oncology: Optimizing chemotherapy and radiotherapy for anaplastic gliomaPatrick G Morris, Andrew B Lassman
Pageof 15